Skip to main content
. 2016 Apr 4;7(19):28096–28111. doi: 10.18632/oncotarget.8581

Figure 8. Lenalidomide treatment does not affect the counts of normal bone marrow plasma cells in allografted patients with multiple myeloma.

Figure 8

Twelve patients with MM who received an allogeneic hematopoietic stem cell transplant were treated with 25 mg lenalidomide daily for 3-18 months. Tumor and normal PCs were regularly monitored. All the patients had stable counts of tumor PCs during lenalidomide treatment. Normal PCs were identified as CD38high, CD19+, CD27+, CD56−, CD117−, CD200− and cytoplasmic Kappa or Lambda Ig light chain+ cells using multicolor cytometry. Data are expressed as the normal PC counts/106 leukocytes in the BM of each patient, harvested before and at different times during lenalidomide treatment. The black bold line represents the mean value of the patients' PC counts.